ProtoMed: Drugs from soybeans

ProtoMed: Drugs from soybeans

Having watched the "early commercialization" strategies at a variety of biotech companies, ProtoMed Inc. President and CEO Louis Scotti thinks he's learned something: the strategy of buying in existing products can't be the basis of an entire company, and it only works if the price is right.

"When you buy a product by definition you are over-paying," said Scotti. "You can do it to open the door, but if you keep doing it, the pyramid falls apart. You get products with low growth